Regeneron Agrees to Lower Drug Prices and Offer Free Hearing-Loss Therapy Under Deal with Trump
Regeneron has agreed to lower U.S. drug prices and offer a new hearing-loss gene therapy for free to eligible patients as part of a deal with President Donald Trump. The company's agreement is part of Trump's 'most favored nation' initiative, which ties U.S. drug prices to the lowest in other developed countries. The deal also includes exemptions from tariffs for three years.
Tickers: $REGN
Topics: drug pricing FDA approval gene therapy healthcare affordability Regeneron